Limits...
Risk factors for increased left ventricular hypertrophy in patients with chronic kidney disease.

Nitta K, Iimuro S, Imai E, Matsuo S, Makino H, Akizawa T, Watanabe T, Ohashi Y, Hishida A - Clin. Exp. Nephrol. (2013)

Bottom Line: LVH was detected in 21.7% of patients at baseline.Cross-sectional baseline data from the CKD-JAC study shed light on the association between LVH and risk factors in patients with decreased renal function.Further longitudinal analyses of the CKD-JAC cohort are needed to evaluate the prognostic value of LVH in CKD patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Medicine, Kidney Center, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan, knitta@kc.twmu.ac.jp.

ABSTRACT

Background: Although left ventricular hypertrophy (LVH) has been established as a predictor of cardiovascular events in chronic kidney disease (CKD), the relationship between the prevalence of LVH and CKD stage during the predialysis period has not been fully examined.

Methods: We measured left ventricular mass index (LVMI) in a cross-sectional cohort of participants in the Chronic Kidney Disease Japan Cohort (CKD-JAC) study in order to identify factors that are associated with increased LVMI in patients with stage 3-5 CKD. LVH was defined as LVMI>125 g/m2 in male patients and >110 g/m2 in female patients.

Results: We analyzed baseline characteristics in 1185 participants (male 63.7%, female 36.3%). Diabetes mellitus was the underlying disease in 41.3% of patients, and mean age was 61.8±11.1 years. LVH was detected in 21.7% of patients at baseline. By multivariate logistic analysis, independent risk factors for LVH were past history of cardiovascular disease (odds ratio [OR] 0.574; 95% confidence interval [CI] 0.360-0.916; P=0.020), systolic blood pressure (OR 1.179; 95% CI 1.021-1.360; P=0.025), body mass index (OR 1.135; 95% CI 1.074-1.200; P<0.001), and serum calcium level (OR 0.589; 95% CI 0.396-0.876; P=0.009).

Conclusion: Cross-sectional baseline data from the CKD-JAC study shed light on the association between LVH and risk factors in patients with decreased renal function. Further longitudinal analyses of the CKD-JAC cohort are needed to evaluate the prognostic value of LVH in CKD patients.

Show MeSH

Related in: MedlinePlus

Comparison of left ventricular mass index (LVMI) in the different subgroups of CKD patients according to their degree of renal dysfunction
© Copyright Policy - OpenAccess
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3824297&req=5

Fig1: Comparison of left ventricular mass index (LVMI) in the different subgroups of CKD patients according to their degree of renal dysfunction

Mentions: LVMI in each of the four groups of CKD patients according to eGFR is shown in Fig. 1, and tended to increase with the stage of CKD (P = 0.0005 in men, P = 0.0016 in women). The prevalence of LVH was 257 of 1185 (21.7 %) of the study population (Table 3). Men had a higher prevalence of LVH than women (15.9 vs 5.7 %).Fig. 1


Risk factors for increased left ventricular hypertrophy in patients with chronic kidney disease.

Nitta K, Iimuro S, Imai E, Matsuo S, Makino H, Akizawa T, Watanabe T, Ohashi Y, Hishida A - Clin. Exp. Nephrol. (2013)

Comparison of left ventricular mass index (LVMI) in the different subgroups of CKD patients according to their degree of renal dysfunction
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3824297&req=5

Fig1: Comparison of left ventricular mass index (LVMI) in the different subgroups of CKD patients according to their degree of renal dysfunction
Mentions: LVMI in each of the four groups of CKD patients according to eGFR is shown in Fig. 1, and tended to increase with the stage of CKD (P = 0.0005 in men, P = 0.0016 in women). The prevalence of LVH was 257 of 1185 (21.7 %) of the study population (Table 3). Men had a higher prevalence of LVH than women (15.9 vs 5.7 %).Fig. 1

Bottom Line: LVH was detected in 21.7% of patients at baseline.Cross-sectional baseline data from the CKD-JAC study shed light on the association between LVH and risk factors in patients with decreased renal function.Further longitudinal analyses of the CKD-JAC cohort are needed to evaluate the prognostic value of LVH in CKD patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Medicine, Kidney Center, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan, knitta@kc.twmu.ac.jp.

ABSTRACT

Background: Although left ventricular hypertrophy (LVH) has been established as a predictor of cardiovascular events in chronic kidney disease (CKD), the relationship between the prevalence of LVH and CKD stage during the predialysis period has not been fully examined.

Methods: We measured left ventricular mass index (LVMI) in a cross-sectional cohort of participants in the Chronic Kidney Disease Japan Cohort (CKD-JAC) study in order to identify factors that are associated with increased LVMI in patients with stage 3-5 CKD. LVH was defined as LVMI>125 g/m2 in male patients and >110 g/m2 in female patients.

Results: We analyzed baseline characteristics in 1185 participants (male 63.7%, female 36.3%). Diabetes mellitus was the underlying disease in 41.3% of patients, and mean age was 61.8±11.1 years. LVH was detected in 21.7% of patients at baseline. By multivariate logistic analysis, independent risk factors for LVH were past history of cardiovascular disease (odds ratio [OR] 0.574; 95% confidence interval [CI] 0.360-0.916; P=0.020), systolic blood pressure (OR 1.179; 95% CI 1.021-1.360; P=0.025), body mass index (OR 1.135; 95% CI 1.074-1.200; P<0.001), and serum calcium level (OR 0.589; 95% CI 0.396-0.876; P=0.009).

Conclusion: Cross-sectional baseline data from the CKD-JAC study shed light on the association between LVH and risk factors in patients with decreased renal function. Further longitudinal analyses of the CKD-JAC cohort are needed to evaluate the prognostic value of LVH in CKD patients.

Show MeSH
Related in: MedlinePlus